Shots:

• The approval is based on four P-III trials including two (EV-001 & EV-002) US trials and European & Canadian i.e TRANSPARENCY study results assessing Jeuveau vs PBO & Botox respectively in 2-100 patients with glabellar lines due to corrugator or procerus muscle activity in adults
• The TRANSPARENCY study collectively resulted in meeting 1EPs (67.5%- 70.4% vs 1.2%- 1.3%) & demonstrated safe and effective results
• Jeuveau (prabotulinumtoxinA-xvfs) injection is a neurotoxin- Type A formulation of 900 kDa purified botulinum toxin developed using Hi-Pure technology with its expected marketing in H1’19

   Ref: Globe Newswire | Image: Evolus